CLINICAL_TRIALS
trial_result
· 2018-02-27
Clinical Trial Update: A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) [Phase 3]
Summary
Phase 3 study of CB-183,315 in Clostridium difficile infection has completed; results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Clostridium Difficile Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-02-27